Kim JS, et al. - In endometrial cancer cells, whether greater anti-proliferative impacts could be seen with metformin (MET)+simvastatin (SIM) combination vs each agent alone. For this purpose, researchers used MET and/or SIM to treat RL95-2, HEC1B, and Ishikawa endometrial cancer cell lines. They used MTS cell proliferation assays to measure growth inhibition. Via caspase-3, Annexin V, and TUNEL assays and by apoptosis markers (BAX, Bcl-2, Bim) using western blot, they assessed apoptosis. They found that endometrial cancer cell viability was synergistically inhibited by MET+SIM treatment. Apoptosis and mTOR pathway inhibition possibly mediate this. As per preclinical evidence generated in this study, further clinical investigation of the combination of these well-tolerated drugs for endometrial cancer therapy may be warranted.